Information Provided By:
Fly News Breaks for February 25, 2020
GILD, TAK, IOVA
Feb 25, 2020 | 14:46 EDT
Stifel analyst Benjamin Burnett notes that Iovance (IOVA) is trading up as a result of a Bloomberg notice that said the company is exploring a sale. The analyst does not know if this is true but does think this is one of the few cell therapy companies in his coverage with data that has been de-risked to a large degree by a proof-of-concept study. From that standpoint, Burnett can see how this might be one of the more interesting cell therapy takeout candidates. However, the analyst has also speculated in the past that the cell therapy M&A thesis is tough to get behind just because this type of acquisition is not likely to be a tuck-in to most buyers. Burnett adds that both Takeda (TAK) and Gilead (GILD) have demonstrated with past deals that they are interested in cell therapy. Because of Kymriah, Novartis (NVS) also comes to mind as a potential buyer, he contends. He reiterates a Buy rating on Iovance's shares, with an unchanged $35 price target.
News For IOVA;TAK;GILD From the Last 2 Days
TAK
Mar 19, 2024 | 06:32 EDT
Centogene (CNTG) announced the extension of an ongoing partnership with Takeda (TAK) to diagnose patients with Lysosomal Storage Disorders. Under the renewed agreement, Centogene will continue to provide Takeda with access to diagnostic testing for patients around the world. The agreement was established to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.